Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 6.3% – What’s Next?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) was up 6.3% during trading on Wednesday . The company traded as high as $11.48 and last traded at $11.45. Approximately 45,696 shares traded hands during trading, a decline of 86% from the average daily volume of 327,551 shares. The stock had previously closed at $10.77.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Canaccord Genuity Group restated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Morgan Stanley dropped their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, November 15th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.38.

Y-mAbs Therapeutics Stock Performance

The company has a 50 day simple moving average of $13.54 and a 200 day simple moving average of $12.81.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. Sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Insider Transactions at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the transaction, the insider now owns 97,681 shares in the company, valued at $1,315,763.07. The trade was a 39.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds have recently modified their holdings of YMAB. Barclays PLC boosted its holdings in Y-mAbs Therapeutics by 433.4% in the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after acquiring an additional 56,244 shares during the period. Empire Financial Management Company LLC acquired a new position in shares of Y-mAbs Therapeutics during the third quarter worth $210,000. Geode Capital Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after purchasing an additional 47,846 shares during the period. State Street Corp grew its holdings in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Finally, Caligan Partners LP increased its stake in Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after buying an additional 613,175 shares during the period. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.